Patently-O: Patent Law Blog (Free subscription) | 4 hours ago
Novo Nordisk v. Caraco Pharma (Fed. Cir. 2009) Unlike most interlocutory orders, the grant or denial of preliminary injunctive relief may be immediately appealed. A district court only awards preliminary injunctive relief after determining that the moving party is likely...
BloggingStocks (Free subscription) | 10/30/2009
Filed under: Earnings reports , Allergan (AGN) One would expect generic U.S. drugmaker Mylan (NYSE: MYL ) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5...
Market Wire (Free subscription) | 10/30/2009
BAGSVAERD, DENMARK (MARKET WIRE) Trading in Novo Nordisk shares by board members, executives and associated persons as reported to Novo Nordisk on 29 October 2009
PR News Wire (Free subscription) | 10/30/2009
PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Novo Nordisk Inc. announced the re-launch of its changing possibilities in hemophilia(TM) campaign through a rebranded Web site and a new community on Facebook®. People living with hemophilia face many daily challenges, and Novo Nordisk is committed to helping this community realize that there is also a lifetime of possibilities.
Red Orbit (Free subscription) | 10/30/2009
PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Novo Nordisk Inc. announced the re-launch of its changing possibilities in hemophilia(TM) campaign through a rebranded Web site and a new community on Facebook®.
Medical News Today (Free subscription) | 10/30/2009
The American Clinical Laboratory Association's Results for Life Campaign (RFL) recognized the National Changing Diabetes Program (NCDP) for funding a newly published study on quality measurement in diabetes care. The NCDP, funded by Novo Nordisk, is a multi-faceted initiative to help bring about dramatic improvement in the prevention and care of diabetes.
njbiz.com Daily (Free subscription) | 10/30/2009
Princeton company aims to replicate success of diabetes treatment for different condition.
PR News Wire (Free subscription) | 10/29/2009
WASHINGTON, Oct. 29 /PRNewswire-USNewswire/ -- The American Clinical Laboratory Association's Results for Life Campaign (RFL) today recognized the National Changing Diabetes Program (NCDP) for funding a newly published study on quality measurement in diabetes care. The NCDP, funded by Novo Nordisk, is a multi-faceted initiative to help bring about dramatic improvement in the prevention and care of...
Contract Pharma Breaking News (Free subscription) | 10/29/2009
Novo Nordisk 3Q09 3Q Revenues: $2.5 billion (+11%) 3Q Earnings: $539.7 million (+3%) YTD Revenues: $7.4 billion (+16%) YTD Earnings: $1.7 million (+21%) Comments: In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%). NovoSeven sales were up 8%, Norditropin sales were up 14%, and Hormone replacement therapy sales were up 12%. North America sales were...
Boston Globe (Free subscription) | 10/29/2009
Danish drug maker Novo Nordisk A/S, the world's top producer of insulin, on Thursday said stronger sales helped boost its third-quarter profit by 3 percent and raised its full-year outlook.
The News Market (Free subscription) | 10/29/2009
Danish pharmaceutical company Novo Nordisk reported a 30% increase in operating profit in the first nine months of 2009 to DKK 11,714 (USD 2,326) million compared to DKK 8,999 (USD 1,787) million
Market Wire (Free subscription) | 10/29/2009
BAGSVAERD, DENMARK (MARKET WIRE) Interim financial report for the period 1 January 2009 to 30 September 2009
Reuters UK (Free subscription) | 10/29/2009
COPENHAGEN, Oct 29 (Reuters) - The world's biggest insulin producer Novo Nordisk reported a bigger-than-forecast increase in operating profits for the third quarter and raised its guidance for 2009 profit growth.
core77.com (Free subscription) | 10/27/2009
Danish medical device company Novo Nordisk has won a Good Design Award for their FlexPen insulin delivery device, which incorporates a needle with a twist--literally: The NovoTwist removeable needle twist-snaps on and off, making it easy for the elderly to swap them out. "Conventional screw thread needles can be difficult to attach and detach, especially for the elderly, as limited manual dexterity...
People Daily (Free subscription) | 10/26/2009
With 86 years of history and around three-fourths of its business engaged in diabetes care, Novo Nordisk maintains more than 50 percent of the insulin market by volume around the world, thanks to its focused strategy. The Denmark-based company said that it will continue this approach in China, which is its fastest-growing market. "We have made a long-term strategic commitment to China, from building...
Videos